The Latin America, Middle East and Africa Plasma Protein Therapeutics Market would witness market growth of 11.3% CAGR during the forecast period (2023-2029).
Idiopathic thrombocytopenic purpura (ITP) is an autoimmune blood condition that results in low platelet counts, which are crucial for blood coagulation. Similarly, Kawasaki Syndrome is the primary cause of cardiac disease in children under five. Failure to diagnose it could lead to heart damage and death. In all of these disorders, plasma protein therapeutics can treat patients, enabling them to live fairly regular lives.
Rising aging and anemic populations also increase the demand for plasma protein therapeutics. The rise in the senior population results from greater life expectancy brought on by technological advancements, advantageous reimbursement policies, as well as improved standards of living. The greatest risk factor for the emergence of cardiovascular, neurological, and other chronic disorders is thought to be aging. Furthermore, the market for plasma protein therapeutics is expanding significantly due to a rise in the adoption of strategies by prominent industry participants. These tactics are intended to help companies increase their market share and product offerings, expanding the market.
The public healthcare system in Brazil offers free comprehensive care to those with hemophilia, as the nation has the third largest proportion of people suffering from hemophilia. A well-coordinated nationwide program must include aspects such as maintaining an up-to-date patient registry, recording the frequency of problems, and evaluating resource utilization efficiency. In 2013, 9,122 patients with hemophilia A were registered in Brazil, of whom 36.1% had a severe condition, according to clinical, sociodemographic, and laboratory data gathered by the Brazilian computerized system on coagulopathies. Hence, the demand for plasma protein therapeutics will increase significantly in the region in the coming years.
The Brazil market dominated the LAMEA Plasma Protein Therapeutics Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $765.3 Million by 2029. The Argentina market is experiencing a CAGR of 11.9% during (2023 - 2029). Additionally, The UAE market would display a CAGR of 11% during (2023 - 2029).
Based on End User, the market is segmented into Hospitals, and Others. Based on Product Type, the market is segmented into Immunoglobulin, Albumin, Plasma derived factor VIII, and Others. Based on Application, the market is segmented into Hemophilia, Idiopathic Thrombocytopenic Purpura, Primary Immunodeficiency Disorder, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Worldwide Plasma Protein Therapeutics Market is Projected to reach USD 39.1 Billion by 2029, at a CAGR of 5.5%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bayer AG, Abeona Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Grifols, S.A., Baxter International, Inc., Kedrion S.p.A, Octapharma AG, CSL Limited (CSL Behring), Taibang Biological Group Co., Ltd and ADMA Biologics, Inc.
Scope of the Study
Market Segments Covered in the Report:
By End User
By Product Type
- Immunoglobulin
- Albumin
- Plasma derived factor VIII
- Others
By Application
- Hemophilia
- Idiopathic Thrombocytopenic Purpura
- Primary Immunodeficiency Disorder
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Bayer AG
- Abeona Therapeutics, Inc.
- Takeda Pharmaceutical Company Limited
- Grifols, S.A.
- Baxter International, Inc.
- Kedrion S.p.A
- Octapharma AG
- CSL Limited (CSL Behring)
- Taibang Biological Group Co., Ltd
- ADMA Biologics, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Plasma Protein Therapeutics Market, by End User
1.4.2 LAMEA Plasma Protein Therapeutics Market, by Product Type
1.4.3 LAMEA Plasma Protein Therapeutics Market, by Application
1.4.4 LAMEA Plasma Protein Therapeutics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Geographical Expansions
3.2.5 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
3.3.2 Key Strategic Move: (Acquisitions and Mergers : 2020, Jun – 2023, Mar) Leading Players
Chapter 4. LAMEA Plasma Protein Therapeutics Market by End User
4.1 LAMEA Hospitals Market by Country
4.2 LAMEA Others Market by Country
Chapter 5. LAMEA Plasma Protein Therapeutics Market by Product Type
5.1 LAMEA Immunoglobulin Market by Country
5.2 LAMEA Albumin Market by Country
5.3 LAMEA Plasma derived factor VIII Market by Country
5.4 LAMEA Others Market by Country
Chapter 6. LAMEA Plasma Protein Therapeutics Market by Application
6.1 LAMEA Hemophilia Market by Country
6.2 LAMEA Idiopathic Thrombocytopenic Purpura Market by Country
6.3 LAMEA Primary Immunodeficiency Disorder Market by Country
6.4 LAMEA Others Market by Country
Chapter 7. LAMEA Plasma Protein Therapeutics Market by Country
7.1 Brazil Plasma Protein Therapeutics Market
7.1.1 Brazil Plasma Protein Therapeutics Market by End User
7.1.2 Brazil Plasma Protein Therapeutics Market by Product Type
7.1.3 Brazil Plasma Protein Therapeutics Market by Application
7.2 Argentina Plasma Protein Therapeutics Market
7.2.1 Argentina Plasma Protein Therapeutics Market by End User
7.2.2 Argentina Plasma Protein Therapeutics Market by Product Type
7.2.3 Argentina Plasma Protein Therapeutics Market by Application
7.3 UAE Plasma Protein Therapeutics Market
7.3.1 UAE Plasma Protein Therapeutics Market by End User
7.3.2 UAE Plasma Protein Therapeutics Market by Product Type
7.3.3 UAE Plasma Protein Therapeutics Market by Application
7.4 Saudi Arabia Plasma Protein Therapeutics Market
7.4.1 Saudi Arabia Plasma Protein Therapeutics Market by End User
7.4.2 Saudi Arabia Plasma Protein Therapeutics Market by Product Type
7.4.3 Saudi Arabia Plasma Protein Therapeutics Market by Application
7.5 South Africa Plasma Protein Therapeutics Market
7.5.1 South Africa Plasma Protein Therapeutics Market by End User
7.5.2 South Africa Plasma Protein Therapeutics Market by Product Type
7.5.3 South Africa Plasma Protein Therapeutics Market by Application
7.6 Nigeria Plasma Protein Therapeutics Market
7.6.1 Nigeria Plasma Protein Therapeutics Market by End User
7.6.2 Nigeria Plasma Protein Therapeutics Market by Product Type
7.6.3 Nigeria Plasma Protein Therapeutics Market by Application
7.7 Rest of LAMEA Plasma Protein Therapeutics Market
7.7.1 Rest of LAMEA Plasma Protein Therapeutics Market by End User
7.7.2 Rest of LAMEA Plasma Protein Therapeutics Market by Product Type
7.7.3 Rest of LAMEA Plasma Protein Therapeutics Market by Application
Chapter 8. Company Profiles
8.1 Bayer AG
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Acquisition and Mergers:
8.1.6 SWOT Analysis
8.2 Grifols, S.A
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Regional & Segmental Analysis
8.2.4 Research & Development Expenses
8.2.5 Recent strategies and developments:
8.2.5.1 Partnerships, Collaborations, and Agreements:
8.2.5.2 Product Launches and Product Expansions:
8.2.5.3 Acquisition and Mergers:
8.2.5.4 Geographical Expansions:
8.3 Takeda Pharmaceutical Company Limited
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.3.5.2 Acquisition and Mergers:
8.3.5.3 Geographical Expansions:
8.4 Kedrion S.p.A
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expenses
8.4.5 Recent strategies and developments:
8.4.5.1 Partnerships, Collaborations, and Agreements:
8.4.5.2 Acquisition and Mergers:
8.5 ADMA Biologics, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 Recent strategies and developments:
8.5.5.1 Approvals and Trials:
8.6 Octapharma AG
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Research & Development Expenses
8.6.4 Recent strategies and developments:
8.6.4.1 Approvals and Trials:
8.7 CSL Limited (CSL Behring)
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expense
8.7.5 Recent strategies and developments:
8.7.5.1 Acquisition and Mergers:
8.8 Baxter International, Inc.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental Analysis
8.8.4 Research & Development Expense
8.9 Abeona Therapeutics, Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Research & Development Expenses
8.10. Taibang Biologic Group
8.10.1 Company Overview
TABLE 1 LAMEA Plasma Protein Therapeutics Market, 2019 - 2022, USD Million
TABLE 2 LAMEA Plasma Protein Therapeutics Market, 2023 - 2029, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Plasma Protein Therapeutics Market
TABLE 4 Product Launches And Product Expansions– Plasma Protein Therapeutics Market
TABLE 5 Acquisition and Mergers– Plasma Protein Therapeutics Market
TABLE 6 Geographical expansions – Plasma Protein Therapeutics Market
TABLE 7 approvals and trials – Plasma Protein Therapeutics Market
TABLE 8 LAMEA Plasma Protein Therapeutics Market by End User, 2019 - 2022, USD Million
TABLE 9 LAMEA Plasma Protein Therapeutics Market by End User, 2023 - 2029, USD Million
TABLE 10 LAMEA Hospitals Market by Country, 2019 - 2022, USD Million
TABLE 11 LAMEA Hospitals Market by Country, 2023 - 2029, USD Million
TABLE 12 LAMEA Others Market by Country, 2019 - 2022, USD Million
TABLE 13 LAMEA Others Market by Country, 2023 - 2029, USD Million
TABLE 14 LAMEA Plasma Protein Therapeutics Market by Product Type, 2019 - 2022, USD Million
TABLE 15 LAMEA Plasma Protein Therapeutics Market by Product Type, 2023 - 2029, USD Million
TABLE 16 LAMEA Immunoglobulin Market by Country, 2019 - 2022, USD Million
TABLE 17 LAMEA Immunoglobulin Market by Country, 2023 - 2029, USD Million
TABLE 18 LAMEA Albumin Market by Country, 2019 - 2022, USD Million
TABLE 19 LAMEA Albumin Market by Country, 2023 - 2029, USD Million
TABLE 20 LAMEA Plasma derived factor VIII Market by Country, 2019 - 2022, USD Million
TABLE 21 LAMEA Plasma derived factor VIII Market by Country, 2023 - 2029, USD Million
TABLE 22 LAMEA Others Market by Country, 2019 - 2022, USD Million
TABLE 23 LAMEA Others Market by Country, 2023 - 2029, USD Million
TABLE 24 LAMEA Plasma Protein Therapeutics Market by Application, 2019 - 2022, USD Million
TABLE 25 LAMEA Plasma Protein Therapeutics Market by Application, 2023 - 2029, USD Million
TABLE 26 LAMEA Hemophilia Market by Country, 2019 - 2022, USD Million
TABLE 27 LAMEA Hemophilia Market by Country, 2023 - 2029, USD Million
TABLE 28 LAMEA Idiopathic Thrombocytopenic Purpura Market by Country, 2019 - 2022, USD Million
TABLE 29 LAMEA Idiopathic Thrombocytopenic Purpura Market by Country, 2023 - 2029, USD Million
TABLE 30 LAMEA Primary Immunodeficiency Disorder Market by Country, 2019 - 2022, USD Million
TABLE 31 LAMEA Primary Immunodeficiency Disorder Market by Country, 2023 - 2029, USD Million
TABLE 32 LAMEA Others Market by Country, 2019 - 2022, USD Million
TABLE 33 LAMEA Others Market by Country, 2023 - 2029, USD Million
TABLE 34 LAMEA Plasma Protein Therapeutics Market by Country, 2019 - 2022, USD Million
TABLE 35 LAMEA Plasma Protein Therapeutics Market by Country, 2023 - 2029, USD Million
TABLE 36 Brazil Plasma Protein Therapeutics Market, 2019 - 2022, USD Million
TABLE 37 Brazil Plasma Protein Therapeutics Market, 2023 - 2029, USD Million
TABLE 38 Brazil Plasma Protein Therapeutics Market by End User, 2019 - 2022, USD Million
TABLE 39 Brazil Plasma Protein Therapeutics Market by End User, 2023 - 2029, USD Million
TABLE 40 Brazil Plasma Protein Therapeutics Market by Product Type, 2019 - 2022, USD Million
TABLE 41 Brazil Plasma Protein Therapeutics Market by Product Type, 2023 - 2029, USD Million
TABLE 42 Brazil Plasma Protein Therapeutics Market by Application, 2019 - 2022, USD Million
TABLE 43 Brazil Plasma Protein Therapeutics Market by Application, 2023 - 2029, USD Million
TABLE 44 Argentina Plasma Protein Therapeutics Market, 2019 - 2022, USD Million
TABLE 45 Argentina Plasma Protein Therapeutics Market, 2023 - 2029, USD Million
TABLE 46 Argentina Plasma Protein Therapeutics Market by End User, 2019 - 2022, USD Million
TABLE 47 Argentina Plasma Protein Therapeutics Market by End User, 2023 - 2029, USD Million
TABLE 48 Argentina Plasma Protein Therapeutics Market by Product Type, 2019 - 2022, USD Million
TABLE 49 Argentina Plasma Protein Therapeutics Market by Product Type, 2023 - 2029, USD Million
TABLE 50 Argentina Plasma Protein Therapeutics Market by Application, 2019 - 2022, USD Million
TABLE 51 Argentina Plasma Protein Therapeutics Market by Application, 2023 - 2029, USD Million
TABLE 52 UAE Plasma Protein Therapeutics Market, 2019 - 2022, USD Million
TABLE 53 UAE Plasma Protein Therapeutics Market, 2023 - 2029, USD Million
TABLE 54 UAE Plasma Protein Therapeutics Market by End User, 2019 - 2022, USD Million
TABLE 55 UAE Plasma Protein Therapeutics Market by End User, 2023 - 2029, USD Million
TABLE 56 UAE Plasma Protein Therapeutics Market by Product Type, 2019 - 2022, USD Million
TABLE 57 UAE Plasma Protein Therapeutics Market by Product Type, 2023 - 2029, USD Million
TABLE 58 UAE Plasma Protein Therapeutics Market by Application, 2019 - 2022, USD Million
TABLE 59 UAE Plasma Protein Therapeutics Market by Application, 2023 - 2029, USD Million
TABLE 60 Saudi Arabia Plasma Protein Therapeutics Market, 2019 - 2022, USD Million
TABLE 61 Saudi Arabia Plasma Protein Therapeutics Market, 2023 - 2029, USD Million
TABLE 62 Saudi Arabia Plasma Protein Therapeutics Market by End User, 2019 - 2022, USD Million
TABLE 63 Saudi Arabia Plasma Protein Therapeutics Market by End User, 2023 - 2029, USD Million
TABLE 64 Saudi Arabia Plasma Protein Therapeutics Market by Product Type, 2019 - 2022, USD Million
TABLE 65 Saudi Arabia Plasma Protein Therapeutics Market by Product Type, 2023 - 2029, USD Million
TABLE 66 Saudi Arabia Plasma Protein Therapeutics Market by Application, 2019 - 2022, USD Million
TABLE 67 Saudi Arabia Plasma Protein Therapeutics Market by Application, 2023 - 2029, USD Million
TABLE 68 South Africa Plasma Protein Therapeutics Market, 2019 - 2022, USD Million
TABLE 69 South Africa Plasma Protein Therapeutics Market, 2023 - 2029, USD Million
TABLE 70 South Africa Plasma Protein Therapeutics Market by End User, 2019 - 2022, USD Million
TABLE 71 South Africa Plasma Protein Therapeutics Market by End User, 2023 - 2029, USD Million
TABLE 72 South Africa Plasma Protein Therapeutics Market by Product Type, 2019 - 2022, USD Million
TABLE 73 South Africa Plasma Protein Therapeutics Market by Product Type, 2023 - 2029, USD Million
TABLE 74 South Africa Plasma Protein Therapeutics Market by Application, 2019 - 2022, USD Million
TABLE 75 South Africa Plasma Protein Therapeutics Market by Application, 2023 - 2029, USD Million
TABLE 76 Nigeria Plasma Protein Therapeutics Market, 2019 - 2022, USD Million
TABLE 77 Nigeria Plasma Protein Therapeutics Market, 2023 - 2029, USD Million
TABLE 78 Nigeria Plasma Protein Therapeutics Market by End User, 2019 - 2022, USD Million
TABLE 79 Nigeria Plasma Protein Therapeutics Market by End User, 2023 - 2029, USD Million
TABLE 80 Nigeria Plasma Protein Therapeutics Market by Product Type, 2019 - 2022, USD Million
TABLE 81 Nigeria Plasma Protein Therapeutics Market by Product Type, 2023 - 2029, USD Million
TABLE 82 Nigeria Plasma Protein Therapeutics Market by Application, 2019 - 2022, USD Million
TABLE 83 Nigeria Plasma Protein Therapeutics Market by Application, 2023 - 2029, USD Million
TABLE 84 Rest of LAMEA Plasma Protein Therapeutics Market, 2019 - 2022, USD Million
TABLE 85 Rest of LAMEA Plasma Protein Therapeutics Market, 2023 - 2029, USD Million
TABLE 86 Rest of LAMEA Plasma Protein Therapeutics Market by End User, 2019 - 2022, USD Million
TABLE 87 Rest of LAMEA Plasma Protein Therapeutics Market by End User, 2023 - 2029, USD Million
TABLE 88 Rest of LAMEA Plasma Protein Therapeutics Market by Product Type, 2019 - 2022, USD Million
TABLE 89 Rest of LAMEA Plasma Protein Therapeutics Market by Product Type, 2023 - 2029, USD Million
TABLE 90 Rest of LAMEA Plasma Protein Therapeutics Market by Application, 2019 - 2022, USD Million
TABLE 91 Rest of LAMEA Plasma Protein Therapeutics Market by Application, 2023 - 2029, USD Million
TABLE 92 Key Information – Bayer AG
TABLE 93 Key information – Grifols, S.A.
TABLE 94 Key Information – Takeda Pharmaceutical Company Limited
TABLE 95 key Information – Kedrion S.p.A
TABLE 96 Key Information – ADMA Biologics, Inc.
TABLE 97 Key Information – Octapharma AG
TABLE 98 key Information – CSL Limited
TABLE 99 Key Information – Baxter International, Inc.
TABLE 100 Key Information – Abeona Therapeutics, Inc.
TABLE 101 Key Information – Taibang Biologic Group
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 4 Key Strategic Move: (Acquisitions and Mergers : 2020, Jun – 2023, Mar) Leading Players
FIG 5 Swot analysis: bayer ag
FIG 6 Recent strategies and developments: Grifols, S.A.
FIG 7 Recent strategies and developments: Takeda Pharmaceutical Company Limited
FIG 8 Recent strategies and developments: Kedrion S.p.A